Main Article Content

Dr. Siddharth Panditray
Dr. Nilamadhaba Prusty
Dr. Rajashree Nayak


Neoadjuvant therapy, perineural invasion, carcinoma, lymphovacular invasion, oral cavity


This study looks at the clinical and segment elements of patients with the oral depression carcinoma getting neoadjuvant treatment to give knowledge into the fundamental factors influencing the course of the sickness and the adequacy of therapy. After 129 members' information were examined, the investigation discovered that men were bound to have it and that it was fundamentally connected with liquor and smoking. Notwithstanding skin and bone attack, buccal mucosa and the underside of the gingivobuccal sulcus are unmistakable subsites that feature the illness' intricacy. Scant data on lymphovascular and perineural attack features regions that need more exploration. Indeed, even with deficient information, the passing rate shows the critical impact that oral depression carcinoma has on the strength of patients. The outcomes highlight the need of explicit therapy plans, careful information gathering, and continuous examination to further develop understanding and organization of neoadjuvant therapy in oral disease.

Abstract 119 | PDF Downloads 82


1. Knochelmann, H.M., Horton, J.D., Liu, S., Armeson, K., Kaczmar, J.M., Wyatt, M.M., Richardson, M.S., Lomeli, S.H., Xiong, Y., Graboyes, E.M. and Lentsch, E.J., 2021. Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma. Cell Reports Medicine, 2(10).
2. Gutiérrez Calderón, V., Cantero González, A., Gálvez Carvajal, L., Aguilar Lizarralde, Y. and Rueda Domínguez, A., 2021. Neoadjuvant immunotherapy in resectable head and neck cancer: oral cavity carcinoma as a potential research model. Therapeutic Advances in Medical Oncology, 13, p.1758835920984061.
3. Liu, S., Knochelmann, H.M., Lomeli, S.H., Hong, A., Richardson, M., Yang, Z., Lim, R.J., Wang, Y., Dumitras, C., Krysan, K. and Timmers, C., 2021. Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma. Cell Reports Medicine, 2(10).
4. Tang, A.L., O’Neil, T., McDermott, S., Tripathi, S., Tikhtman, R., Mark, J.R., Patil, Y., Tabangin, M., Altaye, M., Wise-Draper, T.M. and Zender, C.A., 2022. Association of Neoadjuvant Pembrolizumab for Oral Cavity Squamous Cell Carcinoma With Adverse Events After Surgery in Treatment-Naive Patients. JAMA Otolaryngology–Head & Neck Surgery, 148(10), pp.935-939.
5. Mallick, S. and Giridhar, P., 2020. Neoadjuvant chemotherapy in oral cavity cancer: A new horizon?. Cancer Research, Statistics, and Treatment, 3(2), pp.388-389.
6. Chen, S., Yang, Y., Wang, R. and Fang, J., 2023. Neoadjuvant PD-1/PD-L1 inhibitors combined with chemotherapy had a higher ORR than mono-immunotherapy in untreated HNSCC: Meta-analysis. Oral Oncology, 145, p.106479.
7. Shen-sui, L., Xu-dong, T., Longjiang, L. and Ma, H., 2022. Neoadjuvant Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma: A Single Center Study.
8. Patel, D., Saldanha, E., Joseph, B., Ghosh, S., Dhakad, V. and Desai, S., 2021. Role of Neoadjuvant Chemotherapy in Oral Cavity SCC: A Surgical Oncologists Experience at Tertiary Care Institute. European Journal of Clinical Oncology, 3(1), pp.001-004.
9. Singh, S.P., Sajjan Rajpurohit, D.G.J. and Singh, S., 2021. Neoadjuvant Chemotherapy in Technically Unresectable Oral Cavity Cancers-Are We Heading Towards Paradigm Shift?.
10. Kiong, K.L., Yao, C.M., Lin, F.Y., Bell, D., Ferrarotto, R., Weber, R.S. and Lewis, C.M., 2021. Delay to surgery after neoadjuvant chemotherapy in head and neck squamous cell carcinoma affects oncologic outcomes. Cancer, 127(12), pp.1984-1992.
11. Gupta, A., Banerjee, M., Kantharia, S. and Kantharia, R., 2023. Neoadjuvant Chemotherapy Followed by Surgery in Advanced Oral Squamous Cell Carcinoma-Pathological Response as a Prognostic Indicator?. Journal of Advances in Medicine and Medical Research, 35(20), pp.205-217.
12. More, V.K., Jakhetiya, A., Pandey, A. and Patel, T., 2023. Neoadjuvant Chemotherapy as a viable treatment option for locally Advanced Adenoid Cystic Carcinoma of salivary gland: A case report. SN Comprehensive Clinical Medicine, 5(1), p.86.
13. Tian, Y., Zhang, L., Jin, N., Wan, Z., Zhang, H., Zhang, H. and Zhang, L., 2022. Clinical response to neoadjuvant immunotherapy combined with targeted therapy and chemotherapy in oral squamous cell carcinoma: experience in three patients. OncoTargets and therapy, pp.353-359.
14. Ju, W.T., Xia, R.H., Zhu, D.W., Dou, S.J., Zhu, G.P., Dong, M.J., Wang, L.Z., Sun, Q., Zhao, T.C., Zhou, Z.H. and Liang, S.Y., 2021. Neoadjuvant chemo-free combination of camrelizumab and apatinib for locally advanced resectable oral squamous cell carcinoma–A pilot study.
15. Nindra, Udit, Joshua Hurwitz, Dion Forstner, Venessa Chin, Richard Gallagher, and Jia Liu. "A systematic review of neoadjuvant and definitive immunotherapy in locally advanced head and neck squamous cell carcinoma." Cancer Medicine 12, no. 10 (2023): 11234-11247.
16. Liu, T., Miao, D., Zhang, Y., Jia, P. and Lin, P., 2023. A commentary on “Can adjuvant radiotherapy be omitted for oral cavity cancer patients who received neoadjuvant therapy and surgery? A retrospective cohort study”. International Journal of Surgery, pp.10-1097.

Most read articles by the same author(s)